Natural polysaccharides are used in a variety of applications due to their unique properties. These applications range from paper manufacturing to wound healing . One interesting class of polysaccharides comprises 1,3-β-glucans, which are glucopyranose polysaccharides with (1,3) glycosidic linkages and varying degree of (1,6) branches . 1,3-β-glucans can form single or triple helical structures, which can be used to synthesize resilient gels by applying heat and humidity [3,4]. The properties of these gels are governed by the structure of the polysaccharide, which is determined by the degree of branching and the molecular weight. Thus, controlling the microscopic structure allows control over the macroscopic function. This is especially advantageous in the field of drug delivery because the encapsulation of different agents can be facilitated by the use of different polysaccharides. The properties of 1,3-β-glucans can also be modified by covalently attaching functional units to the polysaccharide backbone .
1,3-β-glucans are derived from microbial  and fungal  sources and hence have innate immunomodulatory properties. When these 1,3-β-glucans are a component of the foreign pathogens, they can act as recognition sites for macrophages to facilitate the elimination and removal of these pathogens . When extracted 1,3-β-glucans are administered to animals or humans, they recruit macrophages and stimulate the immune system through a similar mechanism [8,9]. This result has been utilized for various pharmacological applications including cancer inhibition [10-17], infection resistance [18-21] and wound healing [22-24]. Current research is focusing on combining the structural properties of 1,3-β-glucans with the pharmacological ones to further enhance the efficacy of hybrid systems thus created.
2. Crystallinity of 1,3-β-glucans
1,3-β-glucans are semi-crystalline polysaccharides comprising a combination of single helices, triple helices and random coils. The crystallinity of these polysaccharides has been studied using X-ray diffraction (XRD). In this study, curdlan, which is a linear 1,3-β-glucan, was used as a model polysaccharide . Different forms and states of curdlan demonstrate different crystallinity. One example that was studied in detail is the annealed “dry” state, where the curdlan is dissolved in dimethyl sufoxide, extracted in methanol and annealed in the presence of water at 145 °C. Curdlan is then dried
An alternate structure of curdlan helices is presented based on semi-empirical modeling. It is proposed that hydrogen bonding of the strands occurs along the helix axis rather than perpendicular to it. The different structures are illustrated in Figure 1. It is demonstrated that this alternate structure provides a more stable structure of curdlan and hence is likely to have higher population .
1,3-β-glucans have also been complexed with nucleotides to form crystalline structures. In the example of curdlan and poly(cytidylic acid) complex, semi-empirical modeling suggests that two glucose units of different curdlan chains form hydrogen bonds with one base of the nucleotide chain . This property of curdlan complexing with nucleotides has been exploited in forming liquid crystalline gels with deoxyribonucleic acid (DNA). Such structures could be synthesized at varying scales ranging from nanometers to centimeters .
2.2. Liquid crystalline gels
Curdlan can be used to form liquid crystalline gels when it is exposed to transition metal salts [28,29]. The crystallinity of these gels depends on the molecular weight of the gels . DNA has also been used to synthesize gel beads . When used together, DNA and curdlan provide control over the size and morphology of the synthesized hybrid structures. Various structures can be obtained by modifying the concentration of curdlan and DNA .
Curdlan is insoluble in water but it dissolves in alkaline solutions. Thus, DNA and curdlan are mixed together in a basic solution and then this mixture is added to a solution of calcium chloride salt either directly or through a dialysis membrane. Direct addition leads to formation of structures at the nanometer and millimeter scales. Dialysis allows for the formation of centimeter sized gels. The macroscopic structures are assessed by using crossed nicols (Figure 2), while the nano- and micro-structures are characterized using transmission electron microscopy (TEM, Figure 4). When viewing the centimeter scale gels between two perpendicularly placed polarizers, orthogonal dark lines are observed on the gels. These lines are known as isogyres and indicate the anisotropy in liquid crystalline gels. It is observed that increasing the concentration of DNA decreases the crystallinity of the gel as the isogyres become less defined. This is illustrated in Figure 2 .
A similar phenomenon was observed at the milimeter scale when the structure was observed under the microscope. It was seen that although DNA provided rigidity and well-defined shape to the structure, it reduced the crystallinity. This is likely because DNA forms a less crystalline structure compared to curdlan. It is possible that DNA might not be forming helices with curdlan, but instead forming a gel with microphase separation. The results from millimetre scale are highlighted in Figure 3. The opacity and lack of isogyres in DNA sample implies low crystallinity. Thus, a simple method is presented to determine degree of crystallinity of gels qualitatively .
At the micro- and nano-scale levels, the morphology of the gels could be changed between spheres and fibers by modulating the concentration of the DNA or curdlan. This is summarized in Figure 4. These hybrid liquid crystalline gel systems have the potential of creating advanced drug delivery vehicles where the crystalline regions of the system prevent degradation of the biomolecule and the amorphous regions maintain functionality of the encapsulated moiety. This hybrid system also serves as a tool for further studies of the molecular structure undertaken by 1,3-β-glucan and DNA in various microenvironments .
3. Applications in drug delivery
The ability to control the structure of 1,3-β-glucan based carriers has encouraged the application of these glucans in drug delivery. The glucans can be used as gels, nanoparticles, microparticles or complexes.
3.1. Encapsulation within gels
Curdlan is the commonly used 1,3-β-glucan for formation of gels. Curdlan gels can be prepared by heating the suspension of curdlan in aqueous solution and then cooling it down. If the suspension is heated to 60 °C, a low-set thermally reversible gel is formed whereas if the temperature is above 80 °C, a high-set thermally irreversible gel is formed. Drugs such as indomethacin, salbutamol sulfate and prednisolone have been encapsulated in curdlan gels. The gels are prepared by mixing curdlan in drug solutions at 5-10% curdlan concentration, adding the suspension to a glass test tube, heating the test tube in water bath at the desired temperature for 10 minutes and then unmolding the gel. The experiments conducted in  have demonstrated that a high-set gel can lower the rate of drug release. The curdlan based gels have been able to provide a sustained release of drugs for compared to commercially available formulations. These gels can be used as drug delivery suppositories for rectal administration, which bypasses hepatic first pass clearance .
Curdlan gels have also been used for developing protein delivery devices. Since proteins can denature at high temperatures, the temperature required for forming curdlan gels needs to be lowered. Curdlan can form aqueous gels in the presence of hydrogen bond disrupting agents such as dimethyl sulfoxide, urea and thiocyanates . This property encourages the use of chaotropes for lowering the gelling temperature. It has been demonstrated that the presence of 8 M urea can decrease the gelling temperature of curdlan from 55 °C to 37 °C. This has been used for encapsulating bovine serum albumin (BSA) as a model protein. Although gels synthesized using urea are able to demonstrate sustained release of BSA over 100 hours, the toxicity of urea is a concern. Urea also has the possibility of disrupting the hydrogen bonds of BSA and hence denaturing the protein. Thus, an alternative method of reducing the gelling temperature has been developed by modifying the backbone of curdlan to form a hydroxyethyl derivative. This system was also able to form gels at 37 °C but the BSA release was sustained for a shorter time period of 75 hours .
3.2. Microparticles and nanoparticles
Nanoparticles are typically used in drug delivery applications because of high drug encapsulation efficiency , controlled drug release and incorporation of diagnostic agents [36,37]. One of the major challenges with drug delivery is achieving specificity with cellular uptake. One method of overcoming this hurdle is by attaching targeting ligands on the surface of nanoparticles to allow enhanced uptake by specific cells . Another strategy is the encapsulation of these drug loaded nanoparticle in glucan based microspheres. Glucan microspheres are derived from the cell walls of
Aside from being used as a targeting moiety, 1,3-β-glucans have also been used as structural units for encapsulating insoluble drugs. One example is the use of short chain curdlan with a molecular weight of 990 Da, derived from Vietnam medicinal mushroom
Amphiphilic derivatives of 1,3-β-glucans have also been extensively studied for formation of micellar nanoparticles with drug encapsulating capabilities. One example of an amphiphilic system is based on cholesterol-carboxymethylcurdlan. The hydrophilicity of curdlan is increased by modifying the backbone with carboxymethyl groups. The loading of hydrophobic drugs is increased by inclusion of cholesterol moieties in the curdlan backbone . This system uses a remote loading method for encapsulating epirubicin, where a pH gradient between the interior and exterior of the nanoparticle is utilized to achieve high ratio of drug to carrier . Remote loading method is implemented by preparing blank cholesterol-carboxymethylcurdlan nanoparticles using probe sonication, resuspending dried nanoparticles in ammonium sulfate, performing buffer exchange in sodium chloride and finally adding the desired amount of epirubicin to the solution. This method is able to achieve up to 39.6% drug loading, which is remarkable for polymeric systems. This curdlan based delivery device has been able to enhance the cytotoxicity of epirubicin
Alternatively, curdlan can also be used as the hydrophobic component in an amphiphilic drug delivery vehicle. To achieve this a graft copolymer of curdlan and poly(ethylene glycol) (PEG) has been synthesized . PEG is a commonly used polymer for enhanced biocompatibility [44-48]. Doxorubicin can be incorporated in graft copolymer nanoparticle by nanoprecipitation method. In this technique, the copolymer and drug are dissolved in a common water miscible solvent and then added to magnetically stirred water in a drop-wise manner. The mixing causes self-assembly of polymers where hydrophobic components are at the core of the nanoparticle and hydrophilic components are at the surface. In the case of doxorubicin and curdlan-graft-PEG, dimethyl sulfoxide is used as the common solvent . A schematic of the nanoparticle is presented in Figure 5.
The structure of curdlan-graft-PEG nanoparticles has been confirmed using TEM. The samples were stained using phosphotungstic acid, which acts as a negative stain. This makes the background appear dark and the samples of interest appear bright. Additionally, since phosophotungstic acid is hydrophilic, hydrophobic components will be excluded from the acid and hence appear brighter than hydrophilic components. As observed in Figure 6, the nanoparticles are about 109 nm in size. Doxorubicin is visible as the bright center of the nanoparticles. Figure 6 (B) shows the three distinct layers of the nanoparticle, which correspond well with the schematic presented in Figure 5 .
The doxorubicin formulation with curdlan-graft-PEG was tested
Therefore, nanoparticles and microparticles based on 1,3-β-glucans provide promising opportunities for drug delivery as structural units and as targeting ligands. The combination of these properties can be exploited for developing a drug delivery vehicle with enhanced potency.
3.3. Glucan complexes with polynucleotides
Polynucleotides have found several applications in drug delivery as active agents due to their therapeutic effects [16,41,49]. One of the challenges faced by polynucleotide delivery is their rapid degradation
Hitherto, only homo-sequence polynucleotides have been discussed. Often therapeutic polynucleotides are composed of heterogeneous base pairs. Drug delivery vehicles for hetero-sequence oligonucleotides have also been developed by synthesizing cationic curdlan chains. CpG DNA has demonstrated immune stimulating effects but it needs to be preserved from degradation . Cationic curdlan, synthesized using click chemistry, has been able to form complexes with CpG DNA and increase the cellular uptake in macrophage-like cell line J774.A1. The complex also induces an increase in cytokine (IL-12) secretion, which suggests activation of the macrophage cells . Another strategy of binding hetero-sequence oligonucleotides is by modification of one terminal to attach a homo-sequence such as poly(A). A schizophyllan derivative has been utilized for binding modified antisense oligonucleotides. Schizophyllan has been modified with galactose and PEG units to enhance cellular uptake. It has been observed that the antisense effect was maximized with the use of schizophyllan derivative when the complex is administered to hepatoblastoma HepG2 and melanoma A375 cell lines . Thus, 1,3-β-glucan based drug delivery devices serve as biocompatible carriers for a variety of nucleotides.
4. Applications in immunotherapy
1,3-β-glucans have been known to generate an immune response including stimulation of cytokine production, oxidative burst, increased phagocyte and lymphocyte proliferation as well as phagocytosis of opsonized tissues. Various mechanisms are responsible for this activation and this response has been utilized for varied applications including cancer resistance, disease immunity and wound healing .
4.1. Biological pathways of activation
The complement system is responsible for innate immunity and can be activated by either classical, alternative or lectin pathways. Using lentinan, pachyman and pachymaran polysaccharides, it has been demonstrated that 1,3-β-glucans use the alternative pathway of complement activation for generating an immune response since they show an increased consumption of C3 and C5 proteins from the complement cascade . Additionally, opsonization is an important component of innate immune response. Typically complement protein C3b gets coated on pathogens and is later detected by complement receptor 1 or deactivated to form iC3b for regulation. In the presence of 1,3-β-glucans, iC3b can be detected by complement receptor 3 (CR3) or dectin-1 and this mechanism can be exploited for attacking cancer cells coated with iC3b . Although the effect of CR3 has been negligible in immune activation in murine models [9,58], functional CR3 is essential for phagocytosis in human neutrophils .
Most of the existing studies have focused on macrophages and neutrophils but some 1,3-β-glucans such as lentinan are responsible for stimulation of T-cells and natural killer cells and hence affect the acquired immune response [60,61]. Curdlan has also been used to demonstrate increased proliferation of lymphocytes, which can in turn enhance the immune response . Oxidative burst is yet another immunomodulatory effect that has been demonstrated by 1,3-β-glucans. While curdlan has shown the induction of inducible nitric oxide synthase in rat macrophages , other 1,3-β-glucans have shown an increase in the production of reactive oxygen species . Some studies have demonstrated that immune activation is only possible by linear 1,3-β-glucans  while others emphasize that complex branching is important for most effective stimulation of immune response . Although, several aspects of the biological pathways of activation have been discovered, further studies are necessary to gain a better understanding of the intricate interactions between 1,3-β-glucans and the immune system.
4.2. Tumor suppression
The use of 1,3-β-glucans in cancer therapy has been present in Japan since 1986, where they have been used for gastric, lung and cervical cancers . Lentinan and pachymaran have demonstrated high tumor inhibition ratios of 99.6% and 96%, when tested against subcutaneous implantation of sarcoma 180 in mice . It is hypothesized that the effect of lentinan and pachymaran is highly dependent on the activation of T-lymphocytes because the removal of the thymus from mice caused a suppression of antitumor effects from the 1,3-β-glucans . Additionally, it is also speculated that deactivation of protein helices might be important for antitumor effects because a study has demonstrated that only polysaccharides that deactivated bovine serum albumin showed antitumor activity . Besides lentinan and pachymaran, other 1,3-β-glucans have also exemplified tumor suppression. Some of the prominent examples are scleroglucan with an inhibition ratio of 90.4%, curdlan with inhibition of 99-100% , grifolan with inhibition of 97.9%  and 1,3-β-glucan from
Subsequently, water soluble 1,3-β-glucans have been derived to improve the usability of these polysaccharides. Some examples of these polysaccharides include carboxymethylpachymaran with tumor inhibition ratio of 99.6%, hydroxymethylpachymaran and hydroxypropylpachymaran with up to 100% tumor inhibition when assessed against solid sarcoma 180 at a dose of 5 mg/kg . Several derivatives of curdlan including carboxymethyl, glucosyl, sulfoethyl and sulfopropyl attachments to the backbone have also retained antitumor activity [71,72]. These examples demonstrate the versatility of 1,3-β-glucans in cancer inhibition and thus these polysaccharides can be modified to suit the desired application.
4.3. Infection prevention
Most common infections are caused by bacteria and fungi and since 1,3-β-glucans can induce inflammatory response, these glucans can be used for providing infection resistance. It has been shown that when administering 1,3-β-glucan to mice, their survival against
When considering larger mammals, infection resistance in pigs, dogs and horses has also found applications of 1,3-β-glucans. When piglets were fed with β-glucans after weaning, they demonstrated lower infection from enterotoxigenic
1,3-β-glucans have also been used in aquatic animals as exemplified by the use of schizophyllan with 60-80% survival rate and lentinan and scleroglucan with 55-75% survival rate when tested against
In addition to bacterial and fungal resistance, 1,3-β-glucans have also demonstrated promising results against malaria , herpes simplex virus  and human immunodeficiency virus (HIV) [80-82]. Expanding on HIV research, various complexes have been synthesized with curdlan sulfate in order to enhance the efficacy of the polysaccharide. Some prominent examples include covalent conjugation of azidothymidine to curdlan sulfate for drug delivery to the lymph nodes and bone marrow  and conjugation of fullerene C60 with curdlan for combining their anti-HIV effects .
4.4. Wound healing
1,3-β-glucans can have an impact on wound healing by recruiting macrophages to the wound site  and by increasing collagen deposition . Beta glucan collagen matrix wound dressings have been used in children suffering from partial thickness burns and the dressings were able to simplify wound care by reducing analgesic requirements, improving cosmetic results and eliminating the need for repetitive dressing changes . Other composites of β-glucan have been created with poly(vinyl alcohol)  and chitosan . Poly(vinyl alcohol)/β-glucan composite was able to speed up the wound healing process when tested using rat models and hence decreased the healing time by 48% as compared to cotton gauze . When using a composite of β-glucan and chitosan, a transparent dressing was obtained, which showed better results compared to commercially available chitosan based Beschitin® W. The synthesized chitosan composite did not dissolve during application period and was easy to remove because it did not adhere to wounds .
An assortment of 1,3-β-glucans have been explored for their structural and pharmacological capabilities. The ability of 1,3-β-glucans to form helical structures and gels has been advantageous for forming complexes with small molecules and macromolecules. The immunomodulatory effects of 1,3-β-glucans have served to fight cancer and infections and to promote wound healing. Research is moving towards combining the ability of 1,3-β-glucans to encapsulate bioactive agents with their own bioactivity for creating potent therapeutic devices against current challenges.
This work was financially supported by Natural Sciences and Engineering Research Council of Canada (NSERC) and 20/20 NSERC – Ophthalmic Materials Network. Mohit S. Verma is also financially supported by NSERC Vanier Canada Graduate Scholarship. We would also like to acknowledge Benjamin C. Lehtovaara for his contributions to the outline of this book chapter.
Biomaterials Czaja W. Krystynowicz A. Bielecki S. Brown R. M. Microbial-the cellulose. natural power. to heal. wounds 2006 27 2 145 151
Wasser SP.Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Applied Microbiology and Biotechnology 2002 60 3 258 274
Packing Analysis of Carbohydrates and Polysaccharides.13. Triple-Helical Structure of (1-]3)-Beta-D-Glucan. Macromolecules Deslandes Y. Marchessault R. H. Sarko A. 1980 13 6 1466 1471
McIntire TM, Brant DA.Observations of the (1-> 3)-beta-D-glucan linear triple helix to macrocycle interconversion using noncontact atomic force microscopy. Journal of the American Chemical Society 1998 120 28 6909 6919
Lehtovaara BC, Verma MS, Gu FX.Synthesis of curdlan-graft-poly(ethylene glycol) and formulation of doxorubicin-loaded core-shell nanoparticles. Journal of Bioactive and Compatible Polymers 2012 27 1 3 17
Sutherland IW.Microbial polysaccharides from Gram-negative bacteria. International Dairy Journal 2001 11 9 663 674
The beta-glucan receptor dectin-1 recognizes specific morphologies of Aspergillus fumigatus. Plos Pathogens Steele C. Rapaka R. R. Metz A. Pop S. M. Williams D. L. Gordon S. et al. 2005 1 4 323 334
Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. Journal of Clinical Investigation Vetvicka V. Thornton B. P. Ross G. D. 1996 98 1 50 61
Journal of Experimental Medicine Brown G. D. Herre J. Williams D. L. Willment J. A. Marshall A. S. J. Gordon S. Dectin mediates the. biological effects. of beta-glucans. 2003 197 9 1119 1124
Le Mai Huong, Ha Phuong Thu, Nguyen Thi Bich Thuy, Tran Thi Hong Ha, Ha Thi Minh Thi, Mai Thu Trang, et al.Preparation and Antitumor-promoting Activity of Curcumin Encapsulated by 1,3-beta-Glucan Isolated from Vietnam Medicinal Mushroom Hericium erinaceum. Chemistry Letters 2011 40 8 846 848
Combined yeast-derived beta-glucan with anti-tumor monoclonal antibody for cancer immunotherapy. Experimental and molecular pathology Liu J. Gunn L. Hansen R. Yan J. 2009 86 3 208 214
Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunology Immunotherapy Cheung N. K. V. Modak S. Vickers A. Knuckles B. 2002 51 10 557 564
Self-assembled hydrogel nanoparticles from curdlan derivatives: characterization, anti-cancer drug release and interaction with a hepatoma cell line (HepG2). Journal of Controlled Release Na K. Park K. H. Kim S. W. Bae Y. H. 2000 69 2 225 236
Therapeutic intervention with complement and beta-glucan in cancer. Immunopharmacology Ross G. D. Vetvicka V. Yan J. Xia Y. Vetvickova J. 1999
Anti-Tumor Activity of Carboxymethylglucans obtained by Carboxymethylation of (1-]3)-Beta-D-Glucan from Alcaligenes-Faecalis Var Myxogenes Ifo-13140. European Journal of Cancer Sasaki T. Abiko N. Nitta K. Takasuka N. Sugino Y. Anti 1979 15 2 211 215
Glucan particles for selective delivery of siRNA to phagocytic cells in mice. Biochemical Journal Tesz G. J. Aouadi M. Prot M. Nicoloro S. M. Boutet E. Amano S. U. et al. 2011 436 351 362
Self-assembled nanoparticles of cholesterol-conjugated carboxymethyl curdlan as a novel carrier of epirubicin. Nanotechnology Li L. Gao F. Tang H. Bai Y. Li R. Li X. et al. 2010 21 26 265601 265601
Oral Administration of beta-1,3/1,6-Glucan to Dogs Temporally Changes Total and Antigen-Specific IgA and IgM. Clinical and Vaccine Immunology Stuyven E. Verdonck F. Van Hoek I. Daminet S. Duchateau L. Remon J. P. et al. 2010 17 2 281 285
Distinct Patterns of Dendritic Cell Cytokine Release Stimulated by Fungal beta-Glucans and Toll-Like Receptor Agonists. Infection and Immunity Huang H. Ostroff G. R. Lee C. K. Wang J. P. CA Specht Levitz. S. M. 2009 77 5 1774 1781
Effect of beta-glucans on an ETEC infection in piglets. Veterinary Immunology and Immunopathology Stuyven E. Cox E. Vancaeneghem S. Arnouts S. Deprez P. BM Goddeeris 2009
Benefits of oat beta-glucan on respiratory infection following exercise stress: role of lung macrophages. American Journal of Physiology-Regulatory Integrative and Comparative Physiology Murphy E. A. Davis J. M. AS Brown Carmichael. MD Carson J. A. Van Rooijen N. et al. 2008R 1593R1599.
Preparation and evaluation of a novel wound dressing sheet comprised of beta-glucan-chitosan complex. Reactive & Functional Polymers Kofuji K. Huang Y. Tsubaki K. Kokido F. Nishikawa K. Isobe T. et al. 2010 70 10 784 789
Evaluation of glucan/poly(vinyl alcohol) blend wound dressing using rat models. International Journal of Pharmaceutics Huang M. Yang M. 2008
Effect of macrophage stimulation on collagen biosynthesis in the healing wound. American Surgeon CA Portera Love. E. J. Memore L. Zhang L. Y. Muller A. Browder W. et al. 1997 63 2 125 130
Proposal of a new hydrogen-bonding form to maintain curdlan triple helix. Chemistry & Biodiversity Miyoshi K. Uezu K. Sakurai K. Shinkai S. 2004 1 6 916 924
Structural analysis of the Curdlan/poly(cytidylic acid) complex with semiempirical molecular orbital calculations. Biomacromolecules Miyoshi K. Uezu K. Sakurai K. Shinkai S. Polysaccharide-polynucleotide complexes. Part 3. 2005 6 3 1540 1546
Lehtovaara BC, Verma MS, Gu FX.Multi-phase ionotropic liquid crystalline gels with controlled architecture by self-assembly of biopolymers. Carbohydrate Polymers 2012 87 2 1881 1885
Liquid crystalline gel with refractive index gradient of curdlan. Langmuir Dobashi T. Nobe M. Yoshihara H. Yamamoto T. Konno A. 2004 20 16 6530 6534
Liquid crystalline gel beads of curdlan. Langmuir Dobashi T. Yoshihara H. Nobe M. Koike M. Yamamoto T. Konno A. 2005 21 1 2 4
Molecular weight effect on liquid crystalline gel formation of curdlan. Biomacromolecules Nobe M. Kuroda N. Dobashi T. Yamamoto T. Konno A. Nakata M. 2005 6 6 3373 3379
Langmuir Moran M. C. Miguel M. G. Lindman B. D. N. A. gel particles. Particle preparation. release characteristics. 2007 23 12 6478 6481
Application of Curdlan to Controlled Drug-Delivery.3. Drug-Release from Sustained-Release Suppositories In-Vitro. Biological & Pharmaceutical Bulletin Kanke M. Tanabe E. Katayama H. Koda Y. Yoshitomi H. 1995 18 8 1154 1158
Renn DW.Purified curdlan and its hydroxyalkyl derivatives: preparation, properties and applications. Carbohydrate Polymers 1997 33 4 219 225
Curdlan gels as protein drug delivery vehicles. Biotechnology Letters BS Kim Jung. I. D. Kim J. S. Lee J. Lee I. Y. Lee K. B. 2000 22 14 1127 1130
Size-tunable nanoparticles composed of dextran-b-poly(D,L-lactide) for drug delivery applications. Nano Research MS Verma Liu. S. Chen Y. Y. Meerasa A. Gu F. X. 2012 5 1 49 61
Molecular Pharmaceutics Sun D. Nanotheranostics Integration. of Imaging. Targeted Drug. Delivery 2010 7 6 1879 1879
Nanotechnology and Diagnostic Imaging: New Advances in Contrast Agent Technology. Journal of Nanomedicine & Nanotechnology Rosen J. E. Yoffe S. Meerasa A. MS Verma Gu. F. X. 2011
Therapeutic nanoparticles for drug delivery in cancer. Clinical Cancer Research Cho K. J. Wang X. Nie S. M. Chen Z. Shin D. M. 2008 14 5 1310 1316
Soto ER, Caras AC, Kut LC, Castle MK, Ostroff GR.Glucan particles for macrophage targeted delivery of nanoparticles. Journal of Drug Delivery 2012
Soto ER, Ostroff GR.Characterization of multilayered nanoparticles encapsulated in yeast cell wall particles for DNA delivery. Bioconjugate chemistry 2008 19 4 840 848
- 41. Aouadi M, Tesz GJ, Nicoloro SM, Wang M, Chouinard M, Soto E, et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 2009;458(7242):1180-1184.
Anti cancer effects of curcumin: cycle of life and death. Cell Division Sa G. Das T. 2008
Remote loading of anthracyclines into liposomes. Methods in Molecular Biology Lewrick F. Suss R. 2010 605 139 45
Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proceedings of the National Academy of Sciences of the United States of America Dhar S. Gu F. X. Langer R. Farokhzad O. C. Lippard S. J. 2008 105 45 17356 17361
Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. Journal of Drug Targeting Esmaeili F. Ghahremani M. H. Ostad S. N. Atyabi F. Seyedabadi M. Malekshahi M. R. et al. 2008 16 5 415 423
Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials Cheng J. BA Teply Sherifi. I. Sung J. Luther G. Gu F. X. et al. 2007 28 5 869 876
Development of a nanostructured DNA delivery scaffold via electrospinning of PLGA and PLA-PEG block copolymers. Journal of Controlled Release Luu Y. K. Kim K. BS Hsiao Chu. B. Hadjiargyrou M. 2003 89 2 341 353
Journal of Controlled Release Avgoustakis K. Beletsi A. Panagi Z. Klepetsanis P. Karydas A. G. DS Ithakissios P. L. G. A-m P. E. G. nanoparticles of. cisplatin in. vitro nanoparticle. degradation in. vitro drug. release in vivo. drug residence. in blood. properties 2002
Journal of Immunology Davis H. L. Weeratna R. Waldschmidt T. J. Tygrett L. Schorr J. Krieg A. M. Cp is G. D. N. A. potent a. enhancer of. specific immunity. in mice. immunized with. recombinant hepatitis. B. surface antigen. 1998 160 2 870 876
Chemistry Letters Kimura T. Koumoto K. Sakurai K. Shinkai S. Polysaccharide-polynucleotide complexes. . I. I. I. novel A. interaction between. the beta-1,3-glucan. family the single-stranded. R. N. A. poly C. 2000 2000 11 1242 1243
Chemical modification of curdlan to induce an interaction with poly(C)(1). Chemistry Letters Koumoto K. Kimura T. Kobayashi H. Sakurai K. Shinkai S. 2001 2001 9 908 909
Molecular recognition of adenine, cytosine, and uracil in a single-stranded RNA by a natural polysaccharide: Schizophyllan. Journal of the American Chemical Society Sakurai K. Shinkai S. 2000 122 18 4520 4521
Carbohydrate-appended curdlans as a new family of glycoclusters with binding properties both for a polynucleotide and lectins. Organic & Biomolecular Chemistry Hasegawa T. Numata M. Okumura S. Kimura T. Sakurai K. Shinkai S. 2007 5 15 2404 2412
Krieg A. Cp motifs G. the active. ingredient in. bacterial extracts?. Nature medicine. 2003 9 7 831 835
Biomaterials Karinaga R. Anada T. Minari J. Mizu M. Koumoto K. Fukuda J. et al. Galactose-P E. G. dual conjugation. of beta-(1->. 3. D-glucan schizophyllan. for antisense. oligonucleotides delivery. to enhance. the cellular. uptake 2006 27 8 1626 1635
Lehtovaara BC, Gu FX. Pharmacological, structural, and drug delivery properties and applications of 1,3-beta-glucans.Journal of Agricultural and Food Chemistry 2011 59 13 6813 6828
Solid-Phase Activation of Alternative Pathway of Complement by Beta-1,3-Glucans and its Possible Role for Tumor Regressing Activity. Immunology Hamuro J. Hadding U. Bittersuermann D. Solid 1978 34 4 695 705
Journal of Experimental Medicine Brown G. D. Taylor P. R. Reid D. M. Willment J. A. Williams D. L. Martinez-Pomares L. et al. Dectin is a. major beta-glucan. receptor on. macrophages 2002 196 3 407 412
Molecular Immunology van Bruggen R. Drewniak A. Jansen M. van Houdt M. Roos D. Chapel H. et al. Complement receptor. . not Dectin-. is the. major receptor. on human. neutrophils for. beta-glucan-bearing particles. 2009
Nature Maeda Y. Y. Chihara G. Lentinan a. New-Accelerator Immuno. of-Mediated Cell. Responses 1971 229 5287 634 634
Evaluation of Basic Procedures for Adoptive Immunotherapy for Gastric-Cancer. Biotherapy Fujimoto T. Omote K. Mai M. Natsuumesakai S. 1992 5 2 153 163
The effect of beta-glucans on porcine leukocytes. Veterinary Immunology and Immunopathology Sonck E. Stuyven E. Goddeeris B. Cox E. 2010
Environmental Toxicology and Pharmacology Ljungman A. G. Leanderson P. Tagesson C. (1->-D-glucan 3)-beta. stimulates nitric. oxide generation. cytokine m. R. N. A. expression in. macrophages 1998 5 4 273 281
Antitumour Polysaccharide Derived Chemically from Natural Glucan (Pachyman). Nature Chihara G. Hamuro J. Maeda Y. Arai Y. Fukuoka F. 1970 225 5236 943 944
Antitumor beta-glucan from the cultured fruit body of Agaricus blazei. Biological & Pharmaceutical Bulletin Ohno N. Furukawa M. Miura N. N. Adachi Y. Motoi M. Yadomae T. 2001 24 7 820 828
Bohn JA, BeMiller JN.beta-D-glucans as biological response modifiers: A review of structure-functional activity relationships. Carbohydrate Polymers 1995 28 1 3 14
Effect of Antitumor Polysaccharides on Higher Structure of Serum-Protein. Nature Hamuro J. Chihara G. 1973 245 5419 40 41
Dependence on Chain-Length of Anti-Tumor Activity of (1-]3)-Beta-D-Glucan from Alcaligenes-Faecalis Var Myxogenes, Ifo 13140, and its Acid-Degraded Products. Cancer Research Sasaki T. Abiko N. Sugino Y. Nitta K. 1978 38 2 379 383
Structural Characterization of a Neutral Antitumour Beta-D-Glucan Extracted with Hot Sodium-Hydroxide from Cultured Fruit Bodies of Grifola-Frondosa. Carbohydrate Research Iino K. Ohno N. Suzuki I. Miyazaki T. Yadomae T. 1985 141 1 111 119
Nature Hamuro J. Yamashit Y. Ohsaka Y. Maeda Y. Y. Chihara G. Carboxymethylpachymaran a. New Water. Soluble Polysaccharide. with Marked. Antitumour Activity. 1971 233 5320 486 488
Synthesis and Antitumor-Activity of Derivatives of Curdlan and Lichenan Branched at C-6. Carbohydrate Research Demleitner S. Kraus J. Franz G. 1992 226 2 239 246
Synthesis and Antitumor-Activity of Sulfoalkyl Derivatives of Curdlan and Lichenan. Carbohydrate Research Demleitner S. Kraus J. Franz G. 1992 226 2 247 252
Diluzio NR, Williams DL.Protective Effect of Glucan Against Systemic Staphylococcus-Aureus Septicemia in Normal and Leukemic Mice. Infection and Immunity 1978 20 3 804 810
Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge. Journal of Pharmacology and Experimental Therapeutics Rice P. J. Adams E. L. Ozment-Skelton T. Gonzalez A. J. Goldman M. P. Lockhart B. E. et al. 2005 314 3 1079 1086
The effect of nonspecific immunostimulation of pregnant mares with 1,3/1,6 glucan and levamisole on the immunoglobulins levels in colostrum, selected indices of nonspecific cellular and humoral immunity in foals in neonatal and postnatal period. Veterinary Immunology and Immunopathology Krakowski L. Krzyzanowski J. Wrona Z. Siwicki A. K. 1999 68 1 1 11
Polysaccharide-Induced Protection of Carp, Cyprinus-Carpio L, Against Bacterial-Infection. Journal of Fish Diseases Yano T. Matsuyama H. Mangindaan R. E. P. Polysaccharide 1991 14 5 577 582
Wang WS, Wang DH.Enhancement of the resistance of Tilapia and grass carp to experimental Aeromonas hydrophila and Edwardsiella tarda infections by several polysaccharides. Comparative Immunology Microbiology and Infectious Diseases 1997 20 3 261 270
The effect of curdlan sulphate on development in vitro of Plasmodium falciparum. Transactions of the Royal Society of Tropical Medicine and Hygiene Evans S. G. Morrison D. Kaneko Y. Havlik I. 1998 92 1 87 89
Evaluation of sulfated fungal beta-glucans from the sclerotium of Pleurotus tuber-regium as a potential water-soluble anti-viral agent. Carbohydrate Research Zhang M. Cheung P. C. K. Ooi V. E. C. Zhang L. 2004 339 13 2297 2301
Synthesis and Structural-Analysis of Curdlan Sulfate with a Potent Inhibitory Effect Invitro of Aids Virus-Infection. Macromolecules Yoshida T. Hatanaka K. Uryu T. Kaneko Y. Suzuki E. Miyano H. et al. 1990 23 16 3717 3722
Synthesis and In-Vitro Inhibitory Effect of L-Glycosyl-Branched Curdlan Sulfates on Aids Virus-Infection. Macromolecules Yoshida T. Yasuda Y. Uryu T. Nakashima H. Yamamoto N. Mimura T. et al. 1994 27 22 6272 6276
Synthesis of Curdlan Sulfates having Inhibitory Effects In-Vitro Against Aids Viruses Hiv-1 and Hiv-2. Carbohydrate Research Yoshida T. Yasuda Y. Mimura T. Kaneko Y. Nakashima H. Yamamoto N. et al. 1995 276 2 425 436
Macromolecules Gao Y. Katsuraya K. Kaneko Y. Mimura T. Nakashima H. Uryu T. Synthesis enzymatic. hydrolysis anti-H I. V. activity of. A. Z. T-spacer-curdlan sulfates. 1999 32 25 8319 8324
Syntheses and characterization of water-soluble C-60-curdlan sulfates for biological applications. Journal of Polymer Science Part A-Polymer Chemistry Ungurenasu C. Pinteala M. 2007 45 14 3124 3128
Effect of Enhanced Macrophage Function on Early Wound-Healing. Surgery Browder W. Williams D. Lucore P. Pretus H. Jones E. Mcnamee R. 1988 104 2 224 230
Effectiveness of beta-glucan collagen for treatment of partial-thickness burns in children. Journal of Pediatric Surgery Delatte S. J. Evans J. Hebra A. Adamson W. Othersen H. B. Tagge E. P. 2001 36 1 113 118